Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy

Akın, Semiha; Can, Gülbeyaz; Aydıner, Adnan; Özdilli, Kürşat; Durna, Zehra

doi:10.1016/j.ejon.2010.01.003

Cited by 152 publications

(131 citation statements)

References 28 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…The pattern of symptoms reported in this study is similar to the symptom pattern of lung cancer patients on chemotherapy (Tchekmedyian et al, 2003;Akin et al, 2010). Lung cancer is associated with the highest levels of psychological distress relative to other types of cancer (Walling et al, 2014), possibly due to the physical symptoms of the disease.…”

Section: Discussionsupporting

confidence: 63%

Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy

Thiagarajan

Chan²,

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Much has been done to examine the psychological impact of cancer treatment, but it remains unclear to what extent anxiety and depression is related to symptom prevalence. The present study concerned the characteristics and frequency of distress as related to symptom prevalence in cancer patients undergoing chemotherapy in Malaysia. Materials and Methods: Participants were 303 consecutive adult cancer patients undergoing chemotherapy in an academic medical center. The short form Memorial Symptom Assessment Scale (MSAS-SF), which covers three domains of symptoms (global distress, physical-and psychological symptoms) was used to cross-sectionally measure symptom frequency and associated distress via self-reporting. One-way ANOVA and t-tests were used to test mean differences among MSAS-SF subscale scores. Results: Complete data were available for 303 patients. The mean number of symptoms was 14.5. The five most prevalent were fatigue, dry mouth, hair loss, drowsiness and lack of appetite. Overall, symptom burden and frequency were higher than in other published MSAS-SF studies. Higher symptom frequency was also found to be significantly related to greater distress in cancer patients undergoing chemotherapy. Conclusions: Patients undergoing chemotherapy suffer from multiple physical and psychological symptoms. Better symptom control or palliative care is needed. Greater frequency of reported symptoms may also indicate a subconscious bid by patients for care and reassurance -thus tailored intervention to manage distress should be offered.

show abstract

Section: Discussionsupporting

confidence: 63%

Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy

Thiagarajan

Chan²,

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…However, significant improvement was seen in the symptom scales of cough (p=0.000), haemoptysis (p=0.000) and pain chest (p=0.040) while worsening was found in the symptom scales of sore mouth (p=0.000), dysphagia (p=0.000), peripheral neuropathy (p=0.000) and hair loss (p=0.000) ( Table 6). [11][12][13] Contrary to this Sarna L showed significantly greater disruptions in quality of life in younger patients. Smith et al and Güner P et al showed lower overall quality of life in older patients.…”

Section: Methodsmentioning

confidence: 42%

Quality of life among lung cancer patients undergoing treatment at a tertiary cancer institute in North India

et al. 2016

View full text Add to dashboard Cite

“…Il termine qualità di vita (QoL -Quality of Life) rimanda alla percezione, da parte di un soggetto, del proprio stato di salute fisica, psicologica, sociale, e alla percezione del proprio ruolo nella società e nelle relazioni interpersonali [105]. Nonostante questo concetto sia percepito da ogni individuo, non esiste una definizione univoca di QoL, che è prettamente un aspetto soggettivo e con un significato che può variare molto da individuo a individuo, da popolazione a popolazione, in base alla cultura, al genere, all'età, al livello socio-economico, alle esperienze e alle aspettative.…”

Section: Premessaunclassified

Cetuximab in first line treatment of metastatic colorectal cancer

Barone

Belisari²,

Ciardiello

et al. 2012

View full text Add to dashboard Cite

The present health technology assessment report evaluates the clinical and economic profile of cetuximab in first-line metastatic colorectal cancer (mCRC) in Italy. The first part of the report addresses the epidemiological, clinical, social and economic impact of mCRC. In the second part, evidence of efficacy, safety and cost-effectiveness of cetuximab and its available alternatives is shown. Finally, a model-based economic evaluation aimed at comparing cetuximab-based regimens vs. alternative therapeutic strategies indicated in mCRC in Italy is presented. The model estimates the incremental cost-effectiveness of adding cetuximab to FOLFOX-4 or FOLFIRI based on KRAS status, vs. adding bevacizumab to FOLFOX-4 or vs. FOLFOX-4 or FOLFIRI alone. A theoretical analysis vs. panitumumab has also been performed, despite panitumumab is not yet reimbursed in Italy in first-line mCRC. Survival outcomes, quality of life and costs of patient management are estimated through a Markov model, using the Italian National Healthcare Service (NHS) perspective, over a 10 year period, taking into account KRAS status of patients. The results of the pharmaco-economic analysis show that cetuximab + FOLFOX-4 and cetuximab + FOLFIRI are associated with increased survival, increased cost and increased quality adjusted survival, compared to all other treatments currently indicated and reimbursed in Italy. Adding cetuximab to FOLFOX-4 or FOLFIRI, based on KRAS status shows favorable incremental cost-effectiveness ratio (ICER) vs. adding bevacizumab to FOLFIRI or vs. FOLFOX-4 or FOLFIRI alone. ICER of cetuximab (in combination with FOLFOX-4 or FOLFIRI), compared to currently reimbursed alternatives, is estimated between 6 and 13 thousand Euros per QALY gained, depending on alternative treatment. These estimates are robust in extensive sensitivity analyses. As a final result, both clinical and economic evidence analyzed in this health technology assessment leads to recommend cetuximab as preferred option for the first-line treatment of mCRC KRAS wild-type patients in Italy.

show abstract

Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy

Cited by 152 publications

References 28 publications

Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy

Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy

Quality of life among lung cancer patients undergoing treatment at a tertiary cancer institute in North India

Cetuximab in first line treatment of metastatic colorectal cancer

Contact Info

Product

Resources

About